目的 观察瑞舒伐他汀联合厄贝沙坦对原发性高血压患者氧化应激及血清血管内皮生长因子(VEGF)、胱抑素C(CysC)水平的影响.方法 选择2014年9月—2017年9月河北省邯郸市第一医院急诊内科收治原发性高血压患者90例作为研究对象.按照简单随机法将患者分成观察组及对照组,各45例.对照组患者给予厄贝沙坦治疗,观察组患者在此基础上给予瑞舒伐他汀治疗.治疗4周后,观察2组患者的血压、氧化应激及血清VEGF、CysC水平.结果 与治疗前比较,治疗后观察组及对照组患者的舒张压及收缩压均明显降低(t=12.715、6.931,13.106、4.184,P均=0.000),且观察组降低更明显(t=5.528、4.024,P均=0.000).与治疗前比较,治疗后观察组及对照组谷甘过氧化物酶(GPx)、超氧化物歧化酶(SOD)明显升高,丙二醛(MDA)、8-OHdG,VEGF、CysC水平明显降低(观察组:t=5.191、7.103、7.301、7.201、18.507、6.162;对照组:t=2.503、2.503、2.261、2.998、18.654、3.854,P均<0.05),观察组患者的GPx、SOD升高更明显,MDA、8-OhdG、VEGF、CysC水平降低更明显(t=2.121、3.022、2.299、2.106,7.904、6.324,P均<0.05).结论 瑞舒伐他汀联合厄贝沙坦可有效降低原发性高血压患者的血压及血清VEGF、CysC水平,改善氧化应激反应,有助于改善原发性高血压患者的病情.%Objective To observe the effect of rosuvastatin and Irbesartan on serum VEGF,Cys C and oxidative stress in essential hypertensive patients. Methods Ninety patients with essential hypertension were admitted to our hospital from September 2014 to September 2017 in the Emergency Department of Internal Medicine of First Hospital of Handan City were selected. The patients were divided into observation group and control group according to the simple random method, each group with 45 cases. Patients in the control group were treated with irbesartan only, and patients in the observation group were also treated with rosuvastatin. The blood pressure, serum VEGF, Cys C levels and oxidative stress were observed in the two groups. Results Compared with before treatment, the diastolic blood pressure and systolic blood pressure were significantly lower in the observation group and control group after treatment (t=12. 715, t=6. 931, t=13. 106, t=4. 184, P=0. 000, P=0. 000, P=0. 000, P=0. 000), and the observation group was more significantly reduced (t=5. 528, t=4. 024, P=0. 000, P=0. 000). Compared with before treatment, after treatment, the GPx and SOD in the observation group and the con-trol group increased significantly, MDA and 8 OHdG decreased significantly, and the levels of VEGF and CysC decreased sig-nificantly (t=5. 191,t=7. 103,t=7. 301,t=7. 201,t=2. 503,t=2. 503,t=2. 261,t=2. 998,t=8. 507,t=18. 654,t=6. 162,t=3. 854, P=0. 002, P=0. 000, P=0. 000, P=0. 000, P=0. 014, P=0. 012, P=0. 012, P=0. 011, P=0. 000, P=0. 000, P=0. 000, P=0. 000). The patients in the observation group had more pronounced increases in GPx and SOD. The levels of 8 OHdG, VEGF, and CysC decreased significantly ( t=2. 121, t=3. 022, t=2. 299, t=2. 106, t=7. 904, t=6. 324, P=0. 011, P=0. 017, P=0. 014, P=0. 016, P=0. 000, P=0. 000). Conclusion Rosuvastatin combined with irbesartan can effectively reduce blood pressure and serum VEGF and CysC levels in patients with essential hypertension, and improve the oxidative stress response, which can help to improve the condition of patients with essential hy-pertension.
展开▼
